Bionamic AB is a Swedish biotechnology startup that offers a Software as a Service (SaaS) solution dedicated to antibody R&D data. Their slogan, "The SaaS dedicated to antibody R&D data. Deeper insight, faster results and full traceability," encapsulates their commitment to providing comprehensive and efficient solutions for the biopharma R&D sector.
Founded in 2017 by a team of researchers, Bionamic aims to tackle the challenges associated with digitalization in biopharma R&D. Their software platform serves as a centralized repository for antibody-related discovery and development data, providing a single source of truth and simplifying data navigation. The company emphasizes the importance of representing data in a meaningful way to address real-world problems, reflecting a user-centric approach.
The startup recently secured a significant amount of funding with a kr4.00M Venture Round investment on 28 February 2024, attracting support from notable investors such as I Love Lund, FARO Capital SA, and LU Holding. This latest investment highlights the confidence of these investors in Bionamic's potential and underscores the significance of their contribution to the biotech industry.